CN1107711A - Hypoglycemic compound capsule - Google Patents
Hypoglycemic compound capsule Download PDFInfo
- Publication number
- CN1107711A CN1107711A CN 94101219 CN94101219A CN1107711A CN 1107711 A CN1107711 A CN 1107711A CN 94101219 CN94101219 CN 94101219 CN 94101219 A CN94101219 A CN 94101219A CN 1107711 A CN1107711 A CN 1107711A
- Authority
- CN
- China
- Prior art keywords
- radix
- diabetes
- glibenclamide
- effect
- panacis quinquefolii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The compound hypoglycemic capsule for diabetes is made of 8 raw materials such as American ginseng, coptis root, astragalus root and red sage root based on combination of Chinese with Western medicines and features obvious hypoglycemic effect (95% total effective rate), quick and strong action, and low toxic effect.
Description
The present invention relates to a kind of Tang Wei capsule for the treatment of diabetes, belong to the Chinese medicine and western medicine compound preparation.
Diabetes are a kind of common whole body chronic progressive disease.Because pancreatic is excreting insulin normally, cause insulin relative or absolute not enough, cause sugar, fat, proteinic metabolism disorder, hepatic glycogen and muscle glycogen can not be synthesized.Thereby occurred that blood glucose, glucose in urine raise and carbohydrate tolerance reduces, and typical clinical symptom is polydipsia, polyphagia, polyuria, lose weight etc., " three-many-one-little " symptom, the traditional Chinese medical science claim that diabetes are diabetes." more than three " are " three types of diabetes ".The damage of lung, stomach, kidney is the basis, sick position of diabetes, and the metabolism disorder of water liquid is the material base of diabetes.Diabetic duration length, easy concurrent whole body nerve, blood capillary, macroangiopathy are the more serious endocrine-metabolic diseases of harmful to human.Along with improving constantly of people's living standard, the change of dietary structure, the reduction of labor intensity, the increasing of stress state, its sickness rate is rising gradually.The sickness rate of diabetes is 3-5% in the world, be about 0.7-1% according to China's incomplete statistics, the city is significantly higher than the rural area, interrelated data shows, at present the mortality rate that is caused by diabetes is higher, be only second to diseases such as cardiovascular, cerebrovascular and tumor, therefore positive prevention and treatment diabetes seem very important.The medicine for the treatment of at present diabetes clinically is a lot, can be divided into Western medicine and Chinese medicine two classes basically, and the oral western medicine majority can be than blood sugar lowering faster, but is prone to side effect such as hypoglycemic reaction, gastrointestinal reaction, and eliminates slower to the symptom of diabetes.The symptom of diabetes can be alleviated and eliminate to the Chinese medicine majority preferably, toxic and side effects is less, but blood sugar lowering, glucose in urine more slowly make a general survey of now clinical commonly used in, western drug, all do not reach promptly rapid-action, effect is strong, curative effect is high, toxic and side effects is little, symptom is eliminated fast characteristics.
The object of the present invention is to provide a kind ofly can reach rapid-action to treatment of diabetes, effect is strong, curative effect is high, toxic and side effects is little, symptom is eliminated fast Chinese medicine and western medicine compound preparation-Tang Wei capsule.
The object of the present invention is achieved like this, and it is the application theory of Chinese medical science, adopts the principle for the treatment of both the principal and secondary aspects of a disease, and by adjusting the physiological function of each internal organs of body, reach rapid alleviation and eliminate diabetic symptom, blood sugar lowering, glucose in urine, and poison pair effect is little.
Include Radix Panacis Quinquefolii, Rhizoma Coptidis, the Radix Astragali, Radix Salviae Miltiorrhizae, Radix Puerariae, glibenclamide in its concrete prescription, its proportioning is:
Radix Panacis Quinquefolii: the 3-10%(percentage by weight)
Rhizoma Coptidis: 10-40%
The Radix Astragali: 10-40%
Radix Salviae Miltiorrhizae: 10-40%
Radix Puerariae: 5-30%
Rhizoma Polygonati: 10-30%
Glibenclamide: 2.5-15mg(one daily dose)
Can also add Rhizoma Polygonati and Radix Trichosanthis in above-mentioned prescription, its addition is respectively:
Rhizoma Polygonati: 10-30%
Radix Trichosanthis: 10-30%
Its best prescription is: (preparing 1000 capsules)
Radix Panacis Quinquefolii: 66.7g
The Radix Astragali: 400g
Rhizoma Coptidis: 400g
Rhizoma Polygonati: 200g
Radix Trichosanthis: 200g
Radix Puerariae: 200g
Radix Salviae Miltiorrhizae: 200g
Glibenclamide: 0.5g
Its processing and fabricating method following (is example with above-mentioned optimum formula):
More than eight the flavor medicines, Radix Panacis Quinquefolii and part Rhizoma Coptidis powder are broken into fine powder, sieve, residue Rhizoma Coptidis and the Radix Astragali, Rhizoma Polygonati, Radix Trichosanthis, Radix Puerariae, Radix Salviae Miltiorrhizae Six-element decoct with water secondary, and each 1.5 hours, collecting decoction, filter, be concentrated into relative density 1.25-1.30(50-60 ℃), add Radix Panacis Quinquefolii and Rhizoma Coptidis fine powder, mixing, drying, be ground into middle powder, add glibenclamide and appropriate amount of starch, mixing, the Capsules of packing into goes out 1000 promptly.
The pharmacology of each medicine of distinguishing the flavor of and act on as follows:
Radix Panacis Quinquefolii: the root of Araliaceae Radix Panacis Quinquefolii has lung benefiting the moon, the effect of asthenic fire, promoting the production of body fluid to quench thirst clearly.
The Radix Astragali: the dry root of leguminous plant Radix Astagali or Radix Astragali.Has invigorating QI to consolidate the body surface resistance, diuresis poison holding, evacuation of pus, the effect of expelling pus and promoting granulation.
Rhizoma Coptidis: the dry rhizome of ranunculaceae plant Rhizoma Coptidis, Coptis deltoidea C.Y.Cheng et Hsiao or Coptis Teeta Wall.Has heat clearing and damp drying, the effect of eliminating fire and detoxication.
Rhizoma Polygonati: the dry rhizome of liliaceous plant Yunnan Rhizoma Polygonati, Rhizoma Polygonati or Polygonatum cyrtonema Hua.Effect with boosting qi and nourishing yin, spleen invigorating, lung moistening, kidney tonifying.
Radix Salviae Miltiorrhizae: labiate, the dry root and rhizome of Radix Salviae Miltiorrhizae.Have stasis-dispelling and pain-killing, the latus rectum of invigorating blood circulation, the effect of the relieving restlessness that clears away heart-fire.
Radix Puerariae: leguminous plant, the dry root of Herba Gelsemii Elegantis or Radix Puerariae rattan.Have expelling pathogenic factors from muscles for reducing heat, promote the production of body fluid, rash, the effect of yang invigorating antidiarrheal.
Radix Trichosanthis: the dry root of cucurbitaceous plant Fructus Trichosanthis.Effect with clearing away heat and promoting production of body fluid, detumescence and apocenosis.
Glibenclamide (glyburide)
The N-[2-[4-[[[(ring is amino) carbonyl] amino] sulfonyl] phenyl] ethyl]-2-methoxyl group-5-chlorobenzamide, have hypoglycemic activity.
In the Tang Wei capsule side, Radix Panacis Quinquefolii, Rhizoma Polygonati giving young employees remedial-courses in general knowledge and vocational skills gas the moon, but Radix Panacis Quinquefolii replenishing body fluid and clearing away heat pathogen, Rhizoma Polygonati can the dry nourishing kidney essence of lung moistening.Radix Astragali invigorating the spleen and replenishing QI to be ending frequent micturition, and Radix Trichosanthis, Radix Puerariae Yin-nourishing and body fluid promoting protect Jin Yin with heat clearing away, Rhizoma Coptidis clearing away stomach-heat, and the Radix Salviae Miltiorrhizae blood circulation promoting and blood stasis dispelling improves blood circulation and diabetes height and coagulates high smectic attitude.All medicines cooperate, the merit of playing boosting qi and nourishing yin, clearing heat and moistening dryness, blood circulation promoting and blood stasis dispelling, blood sugar lowering altogether.Compatibility glibenclamide in the side can directly stimulate the beta Cell of islet excreting insulin, strengthens Insulin receptor INSR and postreceptor defects in the surrounding tissue, thus the intensifier target histiocyte to the sensitivity of insulin, i.e. the outer blood sugar reducing function of pancreas.The independent application of glibenclamide easily causes side effect such as hypoglycemia, dyspepsia, diarrhea, cervicodynia, leukopenia.
The Tang Wei capsule is through 120 routine systematic observations, and its blood sugar lowering curative effect obviously is better than matched group glyburide and diabetes pill.Its obvious effective rate reaches 54.17%, and total effective rate reaches 95%, and the glyburide obvious effective rate is 46.67%, and total effective rate is 86.67%, and the diabetes pill obvious effective rate is 36.67%, and total effective rate is 80%.
The Tang Wei capsule only has an example than the hypopathia people comparatively slight hypoglycemic reaction to take place in 120 observed routine cases, recovers after the medicine decrement.And 2 routine hypoglycemic reactions appear in glyburide (glibenclamide) group 30 examples.One routine severe hypoglycemia reaction has appearred in diabetes pill group 30 examples.Prove that thus the probability of Tang Wei capsule generation hypoglycemic reaction and degree are well below glyburide (glibenclamide) and diabetes pill.
The Tang Wei capsule all can alleviate or eliminate symptoms such as thirsty polydipsia, polyuria, polyphagia, weak, spontaneous sweating, dysphoria with feverish sensation in the chest palms and soles rapidly in 120 examples are observed, and effect is lasting, and the tongue fur pulse condition is taken a turn for the better, and its effect is better than diabetes pill and glyburide matched group.
Contain seven flavor Chinese medicine and Western medicine glyburide (glibenclamide) such as Radix Panacis Quinquefolii, Rhizoma Coptidis in the Tang Wei capsule.Clinical effectiveness proves that this medicine ratio is used Western medicine (glibenclamide) and Chinese medicine (removing the Chinese medicine part of glibenclamide) curative effect height separately, effect is fast, and side effect is little.Compare with similar kind diabetes pill, curative effect is higher than diabetes pill, and side effect is littler than diabetes pill.
This medicine is not found any infringement to internal organs such as patient's the heart, Liver and kidney in observed 120 examples.
Advantage of the present invention is that it is the specific drug of treatment type (type of deficiency of both QI and YIN), has characteristics rapid-action, that effect is strong, curative effect is high, toxic and side effects is little, the condition of illness elimination is fast.
Be several embodiments of the present invention below:
Embodiment 1:
Its prescription is: Radix Panacis Quinquefolii 1g, Rhizoma Coptidis 6g, Radix Astragali 6g, Radix Salviae Miltiorrhizae 6g, Radix Puerariae 3g, glibenclamide 7.5mg.
Embodiment 2:
Prescription is: Radix Panacis Quinquefolii 1g, Rhizoma Coptidis 6g, Radix Astragali 6g, Radix Salviae Miltiorrhizae 6g, Radix Puerariae 3g, Rhizoma Polygonati 3g, Radix Trichosanthis 3g, glibenclamide 7.5mg.
Embodiment 3:
Prescription is: Radix Panacis Quinquefolii 0.66g, Rhizoma Coptidis 8.8g, Radix Astragali 8.8g, Radix Salviae Miltiorrhizae 2.54g, Radix Puerariae 1.1g, glibenclamide 2.5mg.
Embodiment 4:
Prescription is: Radix Panacis Quinquefolii 2.2g, Rhizoma Coptidis 2.2g, Radix Astragali 2.2g, Radix Salviae Miltiorrhizae 8.8g, Radix Puerariae 6.6g, glibenclamide 15mg.
Embodiment 5:
Prescription is: Radix Panacis Quinquefolii 0.84g, Rhizoma Coptidis 2.8g, Radix Astragali 2.8g, Radix Salviae Miltiorrhizae 3.36g, Radix Puerariae 1.4g, Rhizoma Polygonati 8.4g, Radix Trichosanthis 8.4g, glibenclamide 7.5mg.
Claims (3)
1, a kind of Tang Wei capsule for the treatment of diabetes is characterized in that its component includes Radix Panacis Quinquefolii, Rhizoma Coptidis, the Radix Astragali, Radix Salviae Miltiorrhizae, Radix Puerariae, glibenclamide, and its proportioning is:
Radix Panacis Quinquefolii: 3-10% (percentage by weight)
Rhizoma Coptidis: 10-40%
The Radix Astragali: 10-40%
Radix Salviae Miltiorrhizae: 10-40%
Radix Puerariae: 5-30%
Rhizoma Polygonati: 10-30%
Glibenclamide: 2.5-15mg (daily dose)
2, Tang Wei capsule according to claim 1 is characterized in that also including Rhizoma Polygonati and Radix Trichosanthis in its component, and its proportioning is respectively:
Rhizoma Polygonati: 10-30%
Radix Trichosanthis: 10-30%
3, Tang Wei capsule according to claim 2 is characterized in that its best prescription is: (preparing 1000 capsules)
Radix Panacis Quinquefolii: 66.7g
The Radix Astragali: 400g
Rhizoma Coptidis: 400g
Rhizoma Polygonati: 200g
Radix Trichosanthis: 200g
Radix Puerariae: 200g
Radix Salviae Miltiorrhizae: 200g
Glibenclamide: 0.5g
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN94101219A CN1066332C (en) | 1994-02-04 | 1994-02-04 | Hypoglycemic compound capsule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN94101219A CN1066332C (en) | 1994-02-04 | 1994-02-04 | Hypoglycemic compound capsule |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1107711A true CN1107711A (en) | 1995-09-06 |
| CN1066332C CN1066332C (en) | 2001-05-30 |
Family
ID=5030052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN94101219A Expired - Fee Related CN1066332C (en) | 1994-02-04 | 1994-02-04 | Hypoglycemic compound capsule |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1066332C (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1305506C (en) * | 2005-10-17 | 2007-03-21 | 高春 | Chinese medicinal pill for treating diabetes mellitus |
| CN100335080C (en) * | 2003-12-12 | 2007-09-05 | 陈永军 | Medication for treating diabetes |
| CN100364559C (en) * | 2005-11-22 | 2008-01-30 | 余内逊 | Method for preparing oral liquid of several micron powders for reducing blood sugar and anti-fatigue |
| CN103340261A (en) * | 2013-06-21 | 2013-10-09 | 庞朝成 | Selenium-rich radix pueraiae bee pollen tea |
| CN103651974A (en) * | 2013-11-22 | 2014-03-26 | 安徽大平油脂有限公司 | Health oil with efficacy of decreasing blood sugar |
| CN104367637A (en) * | 2014-11-06 | 2015-02-25 | 华洪萍 | Traditional Chinese medicine used for treating type 2 diabetes |
| CN107441334A (en) * | 2017-08-11 | 2017-12-08 | 成都风靡生物科技有限公司 | A kind of Chinese medicine composition for treating deficiency of both qi and yin with blood stasis type type II diabetes |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1046633C (en) * | 1992-05-08 | 1999-11-24 | 王德修 | Compound melbine capsule and making process |
-
1994
- 1994-02-04 CN CN94101219A patent/CN1066332C/en not_active Expired - Fee Related
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100335080C (en) * | 2003-12-12 | 2007-09-05 | 陈永军 | Medication for treating diabetes |
| CN1305506C (en) * | 2005-10-17 | 2007-03-21 | 高春 | Chinese medicinal pill for treating diabetes mellitus |
| CN100364559C (en) * | 2005-11-22 | 2008-01-30 | 余内逊 | Method for preparing oral liquid of several micron powders for reducing blood sugar and anti-fatigue |
| CN103340261A (en) * | 2013-06-21 | 2013-10-09 | 庞朝成 | Selenium-rich radix pueraiae bee pollen tea |
| CN103651974A (en) * | 2013-11-22 | 2014-03-26 | 安徽大平油脂有限公司 | Health oil with efficacy of decreasing blood sugar |
| CN104367637A (en) * | 2014-11-06 | 2015-02-25 | 华洪萍 | Traditional Chinese medicine used for treating type 2 diabetes |
| CN107441334A (en) * | 2017-08-11 | 2017-12-08 | 成都风靡生物科技有限公司 | A kind of Chinese medicine composition for treating deficiency of both qi and yin with blood stasis type type II diabetes |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1066332C (en) | 2001-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1079027C (en) | Pharmaceutical composition for diabetes | |
| CN1742939A (en) | Medicine for treating pulmonary fibrosis and preparing method | |
| CN101856405B (en) | Medicinal composition for treating type II diabetes mellitus and preparation method thereof | |
| CN1895619A (en) | Chinese-medicinal composition for preventing and treating liver disease and its preparation | |
| CN1066332C (en) | Hypoglycemic compound capsule | |
| CN1159050C (en) | Compound traditional Chinese medicine preparation for treating type 2 diabetes | |
| CN1879783A (en) | A medicine for treating diabetes | |
| CN1285367C (en) | Medicinal preparation for treating diabetes and its preparation method | |
| CN1053111C (en) | Chinese medical composite preparation with such functions as dispelling toxicity, detoxicating, recuperating, health preserving and face nursing | |
| CN1245197C (en) | Chinese medicine preparation for treating coronary heart disease and viral myocarditis | |
| CN1294948C (en) | Medicine for boosting qi, strengthening spleen and nourishing liver and kidney and its preparation method | |
| CN1272054C (en) | Medicine for treating diabetes and its preparing process | |
| CN1176690C (en) | Medicine for treating chronic nephritis | |
| CN1076622C (en) | Chinese medicine for curing nephritis | |
| CN1126558C (en) | Medicine for treating kidney damage caused by immunological disease lupus erythematosus | |
| CN1186036C (en) | Diabetes treating medicine and its prepn | |
| CN1864728A (en) | Prescription and preparation method of yin-nourishing capsule containing ginseng and astragalus root | |
| CN1223368C (en) | Capsules for nourishing yin and reducing blood sugar | |
| CN1101213C (en) | Diabetes treating medicine | |
| CN1168483C (en) | Heart disease treating medicine | |
| CN1189207C (en) | Chinese medicinal composition for improving human immunity and its preparation method | |
| CN1210049C (en) | Chinese medicine composition for treating diabetes | |
| CN1239179C (en) | Chinese medicine for treating diabetes and preparation method therefor | |
| CN1857644A (en) | Medicine for treating tumor in upper digestive tract and its preparing method | |
| CN1150036A (en) | Glycolipid-gram pharmaceutical composition for treating diabetes involving lower energizer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: HEBEI PROVINCE CANGZHOU TANGSHENG PHARMACEUTICAL C Free format text: FORMER NAME OR ADDRESS: CANGZHOU CHINESE-MEDICINAL PHARMACEUTICAL FACTORY, HEBEI PROV. |
|
| CP01 | Change in the name or title of a patent holder |
Patentee after: Cangzhou Hebei Tang Sheng Pharmaceutical Co., Ltd. Patentee before: Cangzhou Chinese-Medicinal Pharmaceutical Factory, Hebei Prov. |
|
| ASS | Succession or assignment of patent right |
Owner name: SUNNYTWAY PHARMACEUTICAL CO., LTD. HEBEI Free format text: FORMER OWNER: TANGSHENG PHARMACEUTICAL CO., LTD. CANGZHOU, HEBEI Effective date: 20100802 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 061000 NO.8, SOUTH SECTION, JINDE HIGHWAY, CANGZHOU CITY, HEBEI PROVINCE TO: 061000 NO.9, JINGUANG STREET, DEVELOPMENT ZONE, CANGZHOU CITY, HEBEI PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20100802 Address after: 061000 No. nine, golden light street, Cangzhou Development Zone, Hebei Patentee after: Sunnytway Pharmaceutical Co., Ltd. Hebei Address before: 061000 Cangzhou city of Hebei Province Jin De South Highway No. 8 Patentee before: Cangzhou Hebei Tang Sheng Pharmaceutical Co., Ltd. |
|
| ASS | Succession or assignment of patent right |
Owner name: BAISHAN TANGWEI (CANGZHOU) PHARMACEUTICAL CO., LTD Free format text: FORMER OWNER: SUNNYTWAY PHARMACEUTICAL CO., LTD. HEBEI Effective date: 20120121 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20120121 Address after: 061000 Cangzhou economic and Technological Development Zone, Hebei, No. nine main street Patentee after: Baishan Tang Wei (Cangzhou) Pharmaceutical Co. Ltd. Address before: 061000 No. nine, golden light street, Cangzhou Development Zone, Hebei Patentee before: Sunnytway Pharmaceutical Co., Ltd. Hebei |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20010530 Termination date: 20120204 |